Pharma fight! Should you buy GlaxoSmithKline plc, Smith & Nephew plc or Hutchison China MediTech Limited?

Royston Wild considers whether GlaxoSmithKline plc (LON: GSK), Smith & Nephew plc (LON: SN) or Hutchison China MediTech Limited (LON: HCM) is the best destination for wise investors.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I’m weighing up the prospects of London-quoted healthcare giants GlaxoSmithKline (LSE: GSK), Smith & Nephew (LSE: SN) and Hutchison China MediTech (LSE: HCM).

In recovery

GlaxoSmithKline has been a serious casualty of the ‘generics’ wars that has bashed Big Pharma during the past few years.

The medicines giant saw sales of key labels Avodart and Seretide/Advair slump 15% and 13%, respectively, in 2015 against a backcloth of crumbling patent protection encouraging a swathe of new competitors to enter the marketplace.

However, GlaxoSmithKline has thrown the kitchen sink at replacing these blockbuster brands to drive group sales higher again. Indeed, the Brentford firm received marketing approval for its Nucala respiratory treatment in Japan, and Strimvelis rare disease drug in Europe, just in the past few weeks.

The drugs leviathan aims to secure 10 regulatory approvals in key growth areas like COPD in the next two years alone. And GlaxoSmithKline plans to start Phase II and III testing for another 30 potential sales drivers through to the end of 2017.

China star

As the name suggests, Hutchison China MediTech (or ‘Chi-Med’ as it’s popularly known) is aiming to deliver stunning earnings growth by taking Asian marketplaces by storm.

Emerging markets of course represent a key growth segment for the pharmaceuticals sector, where surging GDP expansion is underpinning massive increases in healthcare investment. Indeed, China’s Ministry of Finance plans to hike spending on “healthcare and family planning” by 47.2% in 2016 alone, to CNY12.4bn, Reuters reported in March.

And like GlaxoSmithKline, Chi-Med is embarking on exciting testing programmes to develop its own range of market-leading drugs. Just this month the company commenced ‘first-in-human’ clinical trials of its HMPL-689 small molecule inhibitor for the treatment of hematological cancers, for example.

Joints giant

At the other end of the spectrum, Smith & Nephew is steadily building its position as the world’s leading provider of artificial joints and limbs.

The company saw sales in established markets rise 6% during October-December, the biggest quarterly rise for more than three years. As well as solid organic growth, Smith & Nephew has shrewd purchases like that of ArthroCare in the Sports Medicine segment to thank for this improved performance.

And like GlaxoSmithKline and Chi-Med, Smith & Nephew views developing regions as a critical revenue driver in the years ahead. The joints play saw sales in these territories surge 11% in 2015 despite cyclical weakness in China. And purchases like that of its distributor EuroCiencia Colombia last year underline its faith in the potential of these marketplaces.

So what’s the verdict?

Well, on a pure value basis GlaxoSmithKline nudges ahead of its rivals at the current time. The company deals on a P/E rating of 17.5 times for 2016, and a proposed 80p-per-share dividend yields a smashing 5.3%.

By comparison, Smith & Nephew trades on an earnings multiple of 19.8 times and carries a payout yield of 1.9% (a 22.4p dividend is currently predicted). Meanwhile, Chi-Med is expected to keep racking up losses until 2017 at the earliest, and isn’t anticipated to furnish investors with a dividend any time soon, either.

That said, I believe each of the healthcare stocks here provide terrific long-term potential. Not only should a backcloth of population increases and rising affluence levels power healthcare investment across the globe, but all three operators are doubling-down on product development and acquisition activity to latch onto these positive trends.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 670% in 2 years! This former penny share is skyrocketing on SpaceX contracts

Shares of Filtronic (LON:FTC) were soaring to multi-year highs today after another contract win with SpaceX. Should I buy this…

Read more »

Investing Articles

Why is the Greatland Gold (GGP) share price up 10% today?

Our writer looks at the reasons why the Greatland Gold (GGP) share price is the AIM 100’s best performer today.

Read more »

Passive income text with pin graph chart on business table
Investing Articles

What do I need for a passive income of £100k a year?

How much would I need to invest to collect a very healthy yearly passive income on my retirement? Surprisingly, the…

Read more »

US Stock

£2k invested in Nvidia stock 2 years ago is now worth this boggling amount…

Jon Smith details how much unrealised profit an investor would have from buying Nvidia stock but is cautious about what…

Read more »

Investing Articles

2 value stocks that still look cheap despite the FTSE rally!

Harvey Jones picks out two UK value stocks that still look nicely priced even as the UK index climbs. He…

Read more »

Dividend Shares

I asked ChatGPT to build the perfect passive income portfolio and here’s the result

Jon Smith turns to the world of AI to try and find out whether ChatGPT could build an investor a…

Read more »

Investing Articles

£20,000 to invest? Here’s how the FTSE 100 could deliver a £2,040 passive income

Here are two ways that investors with a lump sum to spend could target a large passive income with FTSE…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Here’s how someone could start investing in 2025 with just £1,000

Planning to start investing in 2025? This writer highlights two very different stocks that might be worth considering for a…

Read more »